Email: cspc@cspc.cn
News
News Center
Sep. 01
2026
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYH2056 TABLETS FOR THE TREATMENT OF DEPRESSION OFFICIALLY INITIATED IN CHINA
Aug. 31
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYH2092 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OVERWEIGHT OR OBESITY OFFICIALLY INITIATED AT
Aug. 28
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2069 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OVERWEIGHT OR OBESITY OFFICIALLY INITIATED AT
Aug. 27
VOLUNTARY ANNOUNCEMENT - HIGHLY POTENT AMYLIN RECEPTOR AGONIST (SYH2092 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Aug. 26
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SYS6010 FOR EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC FOLLOWING FAILURE OF EGFR TKI THERAPY MEETS P
VOLUNTARY ANNOUNCEMENT - SYS6090 (JMT108) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF PATIENTS WITH MSS/pMMR mCRC
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
